Bristol-Myers Squibb (BMS) and BioMotiv, a drug-development accelerator company that is focused on early-stage drug development, have launched Anteros Pharmaceuticals, a biopharmaceutical company focused on developing drugs for fibrotic and other inflammatory diseases.

The intellectual property behind Anteros was first developed by Yale University and in-licensed by BMS and subsequently assigned to Anteros. This is the first company BioMotiv and BMS have launched since executing their strategic partnership agreement as previously announced in September 2019.

Under the terms of the partnership, BMS will contribute intellectual property, data, and reagents for a series of small molecules against an undisclosed mechanism, and BioMotiv, through the formation of Anteros Pharmaceuticals, and in partnership with Yale, will be solely responsible for research and development. Once Anteros nominates a preclinical candidate, BMS has the option to acquire the company from BioMotiv under pre-agreed terms.

BioMotiv is a company associated with The Harrington Project for Discovery & Development, a $340-million initiative, which is focused on advancing early-stage breakthrough discoveries from research institutions into medicines. BioMotiv’s model aligns resources and capital to select, fund, manage and advance a portfolio of drug-development programs.

Source: BioMotiv